Methotrexate for abortion at ≤42 days gestation

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Methotrexate is cytotoxic to trophoblast and, in low doses, has minimal side effects. It is used to treat gestational trophoblastic neoplasia and ectopic pregnancy and has recently been shown to have similar effects on intrauterine trophoblast. A prior study suggested that methotrexate may successfully cause abortion of an early pregnancy without prostaglandin. To test this hypothesis, ten pregnant women at ≤42 days gestation were treated with methotrexate 50 mg/m2 intramuscularly. Vaginal bleeding started 24 ± 10 (mean ± standard deviation) days after the injection and lasted 10 ± 3 days. Methotrexate side effects occurred in 4 patients and were limited to the first 4 days after the injection. Methotrexate alone appears sufficient to abort a very early intrauterine pregnancy.

Original languageEnglish (US)
Pages (from-to)519-525
Number of pages7
JournalContraception
Volume48
Issue number6
DOIs
StatePublished - 1993

    Fingerprint

Keywords

  • Medical abortion
  • methotrexate
  • vaginal ultrasound
  • β-hCG

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this